-40%

Lot4-4 Antique Drug Bottles and Poisons from Merck & Co., Manufacturing Chemists

$ 10.55

Availability: 98 in stock
  • Maker: Merck and Co., Manufacturing Chemists, New York
  • Time Period Manufactured: Pre-1930
  • Color: Brown

    Description

    Lot #4 - 4 Antique Drug Bottles and Poisons from Merck & Co., Manufacturing Chemists, New York
    no reserve auction
    for display purposes only -- not for human consumption
    Each bottle has an intact label
    https://en.wikipedia.org/wiki/Merck_%26_Co.
    Merck & Co., Inc.
    is an American
    multinational
    pharmaceutical
    company headquartered in
    Rahway, New Jersey
    , and is named for
    Merck Group
    , founded in Germany in 1668, of which it was once the American arm. The company does business as
    Merck Sharp & Dohme
    or
    MSD
    outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.
    Merck & Co. traces its origins to its former German parent company
    Merck Group
    , which was established by the
    Merck family
    in 1668 when
    Friedrich Jacob Merck
    purchased a drug store in
    Darmstadt
    .
    In 1827, Merck Group evolved from a pharmacy to a drug manufacturer company with the commercial manufacture of
    morphine
    .
    Merck perfected the chemical process of deriving morphine from
    opium
    and later introduced
    cocaine
    , used to treat sinus problems and to add to beverages to boost energy levels.
    In 1887 a German-born, long-time Merck employee, Theodore Weicker, went to the United States to represent Merck Group.
    In 1891, with 0,000 received from E. Merck, Weicker started Merck & Co., with headquarters in lower Manhattan. That year George Merck, the 23-year-old son of the then head of E. Merck (and grandson of the founder) joined Weicker in New York.
    Merck & Co. operated from 1891 to 1917 as the US subsidiary of the
    Merck Group
    .
    After the U.S. entered
    World War I
    , due to its German connections, Merck & Co. was the subject of
    expropriation
    under the
    Trading with the Enemy Act of 1917
    .
    The government seized 80 percent of the shares owned by the German parent company and sold it.
    In 1919, George F. Merck (head of the American branch of the Merck family), in partnership with
    Goldman Sachs
    and
    Lehman Brothers
    , bought the company back at a U.S. government auction for .5 million, but Merck & Co. remained a separate company from its former German parent.
    Merck & Co. holds the trademark rights to the "Merck" name in the United States and Canada, while its former parent company retains the rights in the rest of the world; the right to use the Merck name was the subject of litigation between the two companies in 2016.
    In 1925,
    George W. Merck
    succeeded his father George F. Merck as president.
    In 1927, the corporation merged with the Powers-
    Weightman
    -Rosengarten Company, a Philadelphia quinine manufacturer.
    George Merck remained president and Frederic Rosengarten became chairman of the board.
    In 1929,
    H. K. Mulford Company
    merged with Sharp and Dohme, Inc. and brought vaccine technology, including immunization of cavalry horses in World War I and delivery of a diphtheria antitoxin to Merck & Co.
    In 1953, Merck & Co. merged with Philadelphia-based Sharp & Dohme, Inc., becoming the largest U.S. drugmaker. Sharp and Dohme had acquired
    H. K. Mulford Company
    in 1929, adding
    smallpox
    vaccines to its portfolio.
    The combined company kept the trade name Merck in the United States and Canada, and as Merck Sharp & Dohme (MSD) outside North America
    .
    In November 2009, Merck & Co. completed a merger with
    Schering-Plough
    in a US billion deal
    .
    Although Merck & Co. was in reality acquiring Schering-Plough, the purchase was declared a "reverse merger", in which "Old" Merck & Co. was renamed Merck Sharp & Dohme, and Schering-Plough renamed as "Merck & Co., Inc. The maneuver was an attempt avoid a "change-of-control" in order to preserve Schering-Plough's rights to market
    Remicade
    . A settlement with
    Johnson & Johnson
    was reached in 2011, in which Merck agreed to pay 0 million.
    Merck Sharp & Dohme remains a subsidiary of the Merck & Co. parent.